Summary: Bank of America Securities expects the European luxury goods sectorial slowdown to continue into the second half of 2024 and 2025 due to a decline in the luxury consumer spending, particularly from the Chinese market.
Full articleSummary: Honeywell had a successful one-hit, scoreless inning in his 2024 big-league debut, entering the game with a six-run lead for the Pirates.
Full articleSummary: Prothena Corporation plc (NASDAQ:PRTA) has entered into a licensing agreement with Bristol Myers Squibb for an investigational drug, PRX019, for neurodegenerative diseases. Prothena will receive an $80 million upfront payment and could get up to $617.5 million in milestone payments, along with royalties on net sales. The FDA has cleared the IND application for PRX019, and Prothena plans to start a Phase 1 clinical trial by the end of 2024, aiming to address diseases caused by protein dysregulation.
Full articleSummary: The Dow Jones Industrial Average touched the 40,000 mark and remained strong, led by blue chips like Walmart and Chubb climbing sharply. The Nasdaq and S&P 500 closed lower. AI and data-center-related companies retraced after gains. The insurance giant Chubb became a major Warren Buffett holding.
Full articleSummary: Five REITs have recently received price target hikes from Mizuho analysts, including VICI Properties, Realty Income Corp, Essential Properties Realty Trust Inc, Agree Realty Corporation, and Welltower Inc.
Full articleSummary: Prothena Corporation plc reported financial results for the first quarter of 2024 and provided business highlights including progress in clinical programs for various neurodegenerative diseases and rare peripheral amyloid diseases, and announced upcoming clinical milestones. They also shared their first quarter financial results.
Full articleSummary: Prothena Corporation plc (NASDAQ:PRTA) reported financial results for the first quarter of 2024, including a net loss of $72.2 million. The company highlighted ongoing clinical programs and upcoming milestones in Alzheimer's disease, Parkinson's disease, neurodegenerative diseases, and rare peripheral amyloid diseases portfolio. Prothena also provided insights into its financial guidance for the year 2024.
Full articleSummary: Prothena Corporation plc announced that members of its senior management team will participate in a fireside chat at the 2023 Bank of America Healthcare Conference. A live webcast will be available through the investor relations section of the Company's website.
Full articleSummary: Prothena to receive $80 million from Bristol Myers Squibb for exclusive US license to PRX005; Next option for worldwide rights following completion of Phase 1. Prothena announced that Bristol Myers Squibb exercised its option under the global neuroscience research and development collaboration to enter into an exclusive U.S. license for PRX005 and will pay Prothena $80 million. Phase 1 study with PRX005 has initiated.
Full article